Search

Haemagglutinin-strain B (Victoria-like)

Zoliflodacin

[A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking … FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803]

Penicillamine

It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties. … Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine).

Depulfavirine

Depulfavirine is under investigation in clinical trial NCT05204394 (Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2nrtis From the 1st Line Standard of Care Therapy).

Natalizumab

In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy

Grazoprevir

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy … It can be used in patients with compensated cirrhosis, human immunodeficiency virus co-infection, or severe kidney disease.

Disopyramide

It also possesses some anticholinergic and local anesthetic properties. … A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar

Abrocitinib

[L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products, … [L39779] Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.[L42395]

Aprocitentan

[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]

Capsicum oleoresin

Capsicum oleoresin is contained in pepper sprays when suspended in water, and acts an active lachrymatory agent that induces irritation, lacrimation, pain, and temporary blindness when in contact with … Capsicum oleoresin is an oily organic resin derived from the fruit of plants in the Capsicum genus, such as chilli peppers.